This site is intended for healthcare professionals

The FDA has accepted the sBLA for Imfinzi and granted Priority Review in the US for a new four-week, fixed-dose regimen for NSCLC and bladder cancer-AstraZeneca.

Read time: 1 mins
Last updated:28th Jun 2021
Published:19th Aug 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest